Seminars in Oncology

Papers
(The TQCC of Seminars in Oncology is 5. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)
ArticleCitations
Clinical efficacy and security analysis of DEB-TACE combined with trans arterial infusion of carrelizumab in the therapy of advanced liver cancer83
Airway disorders associated with immune checkpoint inhibitor therapy: Two case reports and a systematic review73
Masthead44
Breaking barriers: Deciphering the mechanisms of Olaparib resistance in prostate cancer40
Overexpression of CAD in stomach adenocarcinoma tissues and its clinical significance34
Unlocking the therapeutic potential of polyphenols: Promising advances and future directions in pancreatic cancer treatment27
Pretreatment eosinophilia as a biomarker for adverse outcomes in non-small cell lung cancer patients receiving immune checkpoint inhibitors: A systematic review and meta-analysis25
Hepatitis B Virus Reactivation in Cancer Patients Receiving Chemotherapy—A Systematic Review and Meta-Analysis22
Integrated analysis of scRNA-seq and bulk RNA-seq data identifies BHLHE40 as a key gene in pancreatic cancer progression and gemcitabine resistance21
Table of Contents20
Psoas muscle depletion correlates with poor prognosis and compromised immunity in resectable gastric cancer: A multicenter study18
Influence of Cancer on COVID-19 Incidence, Outcomes, and Vaccine Effectiveness: A Prospective Cohort Study of U.S. Veterans18
Editorial Board16
Role of neoadjuvant pembrolizumab in advanced melanoma16
Deciphering the US Regulatory Framework: Comparison Between Oncology Biosimilars and Reference Biologics15
Editorial Board13
Explainable machine learning and feature interpretation to predict survival outcomes in the treatment of lung cancer13
Adenocarcinoma on retrorectal cystic hamartoma: An illustrative image for a very rare diagnosis12
Advancing personalized medicine in LMICs: Predictive indicators for cervical cancer immunotherapy response12
Editorial Board12
Assessment of PSA responses and changes in the rate of tumor growth -rate with immune checkpoint inhibitors in US Veterans with prostate cancer11
Masthead11
Prostate cancer: Evolution of multiparametric MRI PI-RADS v2.1 toward biparametric MRI S-PI-RADS11
Editorial Board11
Masthead10
Genome editing of immune checkpoints: CRISPR-mediated PD-1 inhibition in cancer10
Masthead10
The interest of therapeutic and pharmacological drug monitoring of methotrexate: A systematic review10
Acute liver failure secondary to malignant infiltration: A single center experience10
Editorial Board9
Lactylation in radiosensitivity regulation: Mechanistic insights and recent advances9
Breast cancer exosomes: Managing macrophage polarization and immune regulation in the tumor microenvironment9
Role of magnolol in gastrointestinal cancers: Recent trends and future perspectives9
The nervous system in prostate cancer: A basic science and clinical perspective9
Impact of the COVID-19 Pandemic on the Wellbeing of International Oncology and Hematology Fellows at the Princess Margaret Cancer Center (PMCC)9
Atezolizumab plus bevacizumab versus Lenvatinib for patients with Barcelona clinic liver cancer stage B (BCLC-B) hepatocellular carcinoma (HCC): A real-world population8
Editorial Board8
Screening Adherence for Second Primary Malignancies in Breast Cancer Survivors: Behaviors, Facilitators, and Barriers to Enhance Quality Care8
The challenges of selecting cancer medicines for the WHO Essential Medicines List with the elephant in the room: A path forward8
The effects of microbiota-derived short-chain fatty acids on T lymphocytes: From autoimmune diseases to cancer8
MicroRNAs: From Bench to Bedside Applications as Breast Cancer Therapeutics7
A narrative review of the principal glucocorticoids employed in cancer7
Mapping the epidemiology of cancer-related anemia: A systematic scoping review of global prevalence and incidence7
Post-translational regulation of steroidogenesis and its clinical relevance in hormone responsive cancers7
Hexokinases in gastrointestinal cancers: From molecular insights to therapeutic opportunities7
Risk of intensive care unit admission after immune checkpoint inhibitor use in cancer7
High tumor mutation burden mitigates the negative impact of chemotherapy history on immune checkpoint blockade therapy6
Recent updates on novel heterocyclic scaffolds of anticancer potential as emerging tubulin inhibitors6
Colorectal cancer in Ethiopia: Epidemiological trends, diagnostic and laboratory capacities, and challenges6
Multiple myeloma: Insights into underlying mechanisms, advances in diagnostic and therapeutic modalities6
Editorial Board6
Primary adrenal insufficiency induced by immune checkpoint inhibitors: biological, clinical, and radiological aspects6
Tumor tough, therapy smarter: Rethinking CAR-T for pancreatic cancer5
Masthead5
Advances and challenges in cancer immunotherapy: Strategies for personalized treatment5
Editorial Board5
Exosomal circular RNAs as drivers of temozolomide resistance in glioblastoma: Mechanisms and implications5
Unveiling the role of RAI14 in cancer: Biological significance and translational perspectives5
0.09509015083313